soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Reduces CV Events in T2DM โ (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine ๐งช T2DM + ASCVD/CKD ๐ Oral semaglutide 14 mg vs placebo ๐ New data from the SOUL
Description
Injecting semaglutide into a vein instead of under the skin can cause serious medical complications
The same number of people lost coverage for Wegovy, according to an analysis by GoodRx, a drug discount website.
Compralo en Farmaplus
Learn about the risk, safety guidelines, and how to minimise complications during treatment.
The formula is formulated by glp1 patches experts to provide you with daily care and comprehensive health support
